What is the current state of pramlintide in the market

The substance (medicine Symlin, pramlintide acetate, produced by Amylin Works) has passed the phase III clinical studies and has been administered to a total of 4,800 individuals so far. In the year 2000, an application was submitted to the FDA to allow its promotion in the market but the FDA asked for more explanatory data in the following years. In March 2005 its circulation was approved in the USA as an adjunct treatment for Type 1 and 2 diabetics on insulin who have failed to achieve glycaemic control.

Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook

Post a comment